M THE MANEATER The student voice of MU since 1955
www.themaneater.com
Vol. 85, Issue 19
Feb 13, 2019
MSA
TITLE IX
MSA president hopefuls announce candidacy
It’s On Us Mizzou director Kelli Wilson steps down from position
Solomon Davis and Jennifer Sutterer, both of whom are involved in MSA senate, will vie for the office. ETHAN BROWN AND LINA SIMPKINS
Student Politics Editor Staff Writer
Two candidates — Solomon Davis and Jennifer Sutterer — will run for the office of Missouri Students Association president in 2019. Both candidates have past experience as members of the MSA senate. Davis chairs the senate’s External Affairs Committee, while Sutterer operates as the Budget Committee vice chair, according to the MSA senate’s December 2018 roster. Sutterer and her vice presidential candidate, Mary O’Brien, are running under the “Show Your Stripes” slate. Davis will campaign with Briana Dinwiddie, the slate’s candidate for vice president, under the slate “All In Mizzou.”
Solomon Davis (right), presidential candidate and Briana Dinwiddie, vice presidential candidate (left). Jennifer Sutterer (right), presidential candidate and Mary O’Brien, vice presidential candidate. | COURTESY INSTAGRAM VIA @ALLINMIZZOU | TWITTER VIA @JENANDMARYMIZ
Both candidates’ websites focus on the issues of transportation, college affordability and mental health services for students. Davis and Sutterer are also focusing on expanding the access of emergency menstrual products in bathrooms across campus. MSA senate passed a bill for $2,500 in funding to increase menstrual
product accessibility during the spring 2019 semester, according to previous reporting by The Maneater. The “Show Your Stripes” slate wants to ensure that drugs designed to stabilize overdose victims are offered in dorms, Greek houses and emergency locations
MSA |Page 4
PET HEALTH
MU researchers combat bone cancer in dogs Compared to a three out of 30 survival rate of dogs receiving chemotherapy to treat osteosarcoma, five out of 10 dogs survived the immunotherapy trial. LAURA EVANS
Staff Writer
MU oncology researchers have helped develop a new precision medicine that fights osteosarcoma, a type of bone cancer common in dogs. Jeffrey Bryan, veterinary oncologist and the director of the Comparative Oncology, Radiobiology and Epigenetics Laboratory, helped to design the clinical trial and lead the trial efforts. The researchers partnered with ELIAS Animal Health to carry out research into combating the disease. “It was sponsored by the ELIAS Animal Health company,” Bryan said. “Their
chief scientist Gary Wood developed this immunotherapy approach to treating cancer, and he has tested it previously in human clinical trials as well. They did the work of creating the tumor vaccines.” The idea for this research was brought to the attention of Carolyn Henry, dean of the College of Veterinary Medicine, a few years ago by ELIAS CEO Tammie Wahaus and director Gary Wood. “The osteosarcoma clinical trial is the culmination of a collaboration that started many years ago when I was introduced to Tammie Wahaus and Gary Wood, then of TVAX Biomedical, at a scientific meeting in Kansas City,” Henry said in an email. “They were interested in the animal health market for new cancer therapies, and we were collectively interested in finding better, less toxic treatment options for dogs with cancer.” Though osteosarcoma is most prevalent in dogs, there are rare cases
of humans with the disease. “About 660 to 800 kids get osteosarcoma in the whole country every year,” Bryan said. “The horrible tragedy of that cancer in particular is that it tends to strike preteens and teens. It’s very damaging to the limb. It’s about 10 times as common in dogs. We see over 10,000 cases in dogs in the United States each year, equally as devastating.” Brian Flesner, assistant professor of oncology and a co-investigator in the study, noted that osteosarcoma’s high rate of metastasis, or developing another growth in a different part of the body, makes the disease especially difficult to combat. “This tumor is highly aggressive and has about a 90 percent metastatic rate,” Flesner said. “If you get local control, whether that’s with a definitive surgery or some other means of removing the tumor, 90 percent of dogs will fail distantly. It’ll spread mainly to their lungs. The exciting part of this trial was it was the first one that didn’t involve chemotherapy and showed extended survival in dogs.” The first step in treating dogs with osteosarcoma is amputating the limb
DOG |Page 4
Kelli Wilson, who has been the organization’s director since June 2018, cited personal reasons for stepping down. ETHAN BROWN
Student Politics Editor Kelli Wilson, former director of It’s On Us Mizzou, has stepped down from her role in the organization. MacKinlee Rogers, the organization’s internal assistant director, will assume the position of director. Rogers confirmed Wilson’s resignation Feb. 12 in an email, citing personal reasons as Wilson’s choice to step down. Wilson took over as director in June 2018, according to It’s On Us Mizzou’s Twitter. Rogers said she will operate as the organization’s director until they select a new one in May. “Although my choice to step down as director was public amongst members, I had other private reasons for stepping down and doing what was best for the organization,” Wilson said in an email. Wilson declined to comment further on the resignation, but reiterated her support for the mission of It’s On Us. “As always, the organization is committed to its mission of ending sexual assault on college campuses,” Rogers said in an email. Edited by Anne Clinkenbeard aclinkenbeard@ themaneater.com